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BACKGROUND
Experimental and clinical data suggest that reducing inflammation without affecting lipid 
levels may reduce the risk of cardiovascular disease. Yet, the inflammatory hypothesis of 
atherothrombosis has remained unproved.
METHODS
We conducted a randomized, double-blind trial of canakinumab, a therapeutic monoclonal 
antibody targeting interleukin-1β, involving 10,061 patients with previous myocardial infarc-
tion and a high-sensitivity C-reactive protein level of 2 mg or more per liter. The trial 
compared three doses of canakinumab (50 mg, 150 mg, and 300 mg, administered sub-
cutaneously every 3 months) with placebo. The primary efficacy end point was nonfatal 
myocardial infarction, nonfatal stroke, or cardiovascular death.
RESULTS
At 48 months, the median reduction from baseline in the high-sensitivity C-reactive protein 
level was 26 percentage points greater in the group that received the 50-mg dose of canakinumab, 
37 percentage points greater in the 150-mg group, and 41 percentage points greater in the 
300-mg group than in the placebo group. Canakinumab did not reduce lipid levels from baseline. 
At a median follow-up of 3.7 years, the incidence rate for the primary end point was 4.50 events 
per 100 person-years in the placebo group, 4.11 events per 100 person-years in the 50-mg group, 
3.86 events per 100 person-years in the 150-mg group, and 3.90 events per 100 person-years in 
the 300-mg group. The hazard ratios as compared with placebo were as follows: in the 50-mg 
group, 0.93 (95% confidence interval [CI], 0.80 to 1.07; P = 0.30); in the 150-mg group, 0.85 (95% 
CI, 0.74 to 0.98; P = 0.021); and in the 300-mg group, 0.86 (95% CI, 0.75 to 0.99; P = 0.031). The 
150-mg dose, but not the other doses, met the prespecified multiplicity-adjusted threshold for 
statistical significance for the primary end point and the secondary end point that additionally 
included hospitalization for unstable angina that led to urgent revascularization (hazard ratio vs. 
placebo, 0.83; 95% CI, 0.73 to 0.95; P = 0.005). Canakinumab was associated with a higher inci-
dence of fatal infection than was placebo. There was no significant difference in all-cause mor-
tality (hazard ratio for all canakinumab doses vs. placebo, 0.94; 95% CI, 0.83 to 1.06; P = 0.31).
CONCLUSIONS
Antiinflammatory therapy targeting the interleukin-1β innate immunity pathway with 
canakinumab at a dose of 150 mg every 3 months led to a significantly lower rate of recur-
rent cardiovascular events than placebo, independent of lipid-level lowering. (Funded by 
Novartis; CANTOS ClinicalTrials.gov number, NCT01327846.)
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Current pharmaceutical interven-tions that are designed to slow the progres-sion of atherosclerosis focus almost exclu-
sively on reducing plasma levels of cholesterol. 
However, clinical and experimental data support 
an additional critical role for inflammation in ath-
erothrombosis.1-3 We previously found that down-
stream biomarkers of inflammation such as high-
sensitivity C-reactive protein and interleukin-6 
are associated with an increased risk of cardio-
vascular events, independent of the cholesterol 
level.4,5 We have also found that statins reduce the 
levels of cholesterol and markers of inflamma-
tion,6 and in a series of clinical trials we and 
others subsequently found that beneficial outcomes 
after statin therapy relate to both a reduction in 
cholesterol level and inflammation inhibition.7-11 
Yet, to date, no evidence has shown that reducing 
vascular inflammation in the absence of concomi-
tant lipid lowering reduces the rates of cardiovas-
cular events. As such, the inflammatory hypoth-
esis of atherothrombosis has remained unproved.
Interleukin-1β is a cytokine that is central to 
the inflammatory response and that drives the 
interleukin-6 signaling pathway. Canakinumab, 
a fully human monoclonal antibody targeting 
interleukin-1β, has antiinflammatory effects and 
has been approved for clinical use in rheumato-
logic disorders.12,13 In a phase 2 trial involving 
patients with diabetes who were at high vascular 
risk, we found that interleukin-1β inhibition with 
canakinumab markedly reduced plasma levels of 
interleukin-6 and high-sensitivity C-reactive pro-
tein without lowering the level of low-density 
lipoprotein (LDL) cholesterol.14 Thus, we hypoth-
esized that canakinumab could provide a critical 
proof-of-concept treatment to test the inflamma-
tory hypothesis of atherothrombosis directly. The 
Canakinumab Antiinflammatory Thrombosis Out-
come Study (CANTOS), a randomized, double-
blind, placebo-controlled trial involving stable 
patients with previous myocardial infarction, 
evaluated whether canakinumab could prevent 
recurrent vascular events in men and women 
who have a persistent proinflammatory response, 
defined as a high-sensitivity C-reactive protein 
level of 2 mg or more per liter.15
Me thods
Trial Design and Oversight
This investigator-driven clinical trial was spon-
sored by Novartis. The trial protocol, available with 
the full text of this article at NEJM.org, was de-
signed by academic members of the executive 
committee with input from physician and statis-
tician employees of the sponsor. The protocol was 
approved at participating centers by the respon-
sible institutional review board or ethics com-
mittee, as applicable in the 39 countries involved. 
An independent data and safety monitoring 
committee oversaw the trial. The sponsor was 
responsible for data collection. The first author 
and an academic statistician at Brigham and 
Women’s Hospital had full access to the trial 
databases, generated trial analyses, prepared the 
first draft of the manuscript, and made the deci-
sion to submit the manuscript for publication. 
The authors assume responsibility for the accu-
racy and completeness of the data and analyses 
and for the fidelity of the trial to the protocol.
Trial Population
Patients were eligible for enrollment if they had 
a history of myocardial infarction and had a 
blood level of high-sensitivity C-reactive protein 
of 2 mg or more per liter despite the use of ag-
gressive secondary prevention strategies. The trial 
excluded from enrollment patients with a history 
of chronic or recurrent infection, previous can-
cer other than basal-cell skin carcinoma, a sus-
pected or known immunocompromised state, a 
history or high risk of tuberculosis or disease 
related to the human immunodeficiency virus, 
or ongoing use of other systemic antiinflamma-
tory treatments. Details of the inclusion and ex-
clusion criteria are provided in Section B in the 
Supplementary Appendix, available at NEJM.org.
Randomization
Initially, patients were randomly assigned in a 
1:1:1 ratio to receive placebo, canakinumab at a 
dose of 150 mg, or canakinumab at a dose of 
300 mg. After the enrollment of 741 patients, a 
50-mg dose of canakinumab was added at the 
request of a regulatory agency, and the random-
ization ratio was adjusted accordingly; we sought 
to achieve a final randomization ratio of 1.5 
(placebo group):1:1:1 (Section C in the Supple-
mentary Appendix). All doses of canakinumab 
and placebo were administered subcutaneously 
once every 3 months; for the 300-mg dose, the 
regimen was 300 mg every 2 weeks for the first 
two doses, then once every 3 months. Randomiza-
tion was performed with the use of a centralized 
computer system, with stratification according 
A Quick Take 
is available at 
NEJM.org
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to the time since the index myocardial infarction 
and according to trial part (before vs. after inclu-
sion of the 50-mg dose group).
End Points
The primary efficacy end point was the first oc-
currence of nonfatal myocardial infarction, any 
nonfatal stroke, or cardiovascular death in a 
time-to-event analysis. The trial had two key 
secondary efficacy end points. The first key sec-
ondary end point included the components of 
the primary end point as well as hospitalization 
for unstable angina that led to urgent revascular-
ization. The second key secondary end point, the 
incidence of new-onset type 2 diabetes among 
patients with prediabetes at randomization in a 
time-to-event analysis, is not reported here. The 
two other prespecified secondary end points were 
death from any cause and the composite of non-
fatal myocardial infarction, any nonfatal stroke, 
or death from any cause. All the components of 
these end points were adjudicated by an end-point 
adjudication committee, whose members were 
unaware of the trial-group assignments.
Statistical Analysis
The trial was designed to accrue a total of 1400 
primary end-point events across all the groups. 
Assuming that all three active doses would re-
sult in a primary event rate that was 20% lower 
than the rate with placebo, we calculated that 
the trial would have more than 90% power to 
detect a significantly lower risk with at least one 
canakinumab dose than with placebo. The inves-
tigators initially sought to enroll 17,200 patients 
in order to accrue 1400 events over a period of 
5 years. In December 2013, at the request of the 
sponsor, the sample size was reduced to 10,000 
patients. The planned follow-up was extended by 
1 year to maintain the targeted number of events.
The distributions of the percentage change 
from baseline in the high-sensitivity C-reactive 
protein and lipid levels were compared between 
the placebo group and each canakinumab group 
at intervals up to 48 months. Similar comparisons 
were made for interleukin-6 levels up to 12 months. 
Log-rank tests and Cox proportional-hazards 
models, stratified according to the time since 
the index myocardial infarction and according 
to trial part, were used to analyze the prespec-
ified primary and key secondary cardiovascular 
end points that occurred during trial follow-up, 
according to the intention-to-treat principle.
The formal evaluation of significance for indi-
vidual doses, with adjustment for multiple com-
parisons, followed a closed testing procedure 
(Section C in the Supplementary Appendix). On 
the basis of the closed testing procedure, and 
with the use of the prespecified allocation of 
alpha error, the two-sided P value thresholds for 
statistical significance for the primary end point 
were 0.01058 for the test of the 300-mg dose of 
canakinumab versus placebo and 0.02115 for the 
tests of the other two doses versus placebo. The 
closed testing procedure also specified that for-
mal significance testing for the key secondary 
end points would be performed for any given 
dose only if the significance threshold for the 
primary end point for that dose had been met.
Although the primary analysis strategy was 
based on pairwise comparisons of individual dose 
groups with the placebo group, comparisons 
were also made between the incidence rates in 
the placebo group and the incidence rates across 
the ascending canakinumab doses (using scores 
of 0, 1, 3, and 6 that were proportional to doses 
in a trend analysis) and in the combined cana-
kinumab groups versus placebo. In addition, 
analyses that focused on patients who adhered 
to the trial regimen were performed, with follow-
up for each patient being censored 119 days after 
the last injection was received. The significance 
thresholds for these tests were not adjusted for 
multiple comparisons. Similar analyses were used 
for adverse events. All P values are two-sided, 
and all confidence intervals were computed at 
the 95% level.
R esult s
Patients
Trial enrollment began in April 2011 and was 
completed in March 2014; the last trial visit was 
in June 2017. Of 17,482 patients who had previ-
ously had myocardial infarction and had under-
gone screening in the central laboratory, 10,061 
(57.6%) underwent randomization correctly and 
received at least one dose of canakinumab or 
placebo (Fig. S1 in the Supplementary Appendix). 
The most common reasons for exclusion were a 
high-sensitivity C-reactive protein level of less 
than 2 mg per liter (46.0% of the excluded pa-
tients), active tuberculosis or tuberculosis risk 
factors (25.4%), and exclusionary concomitant 
disorders (9.9%).
The mean age of the participants who under-
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went randomization was 61 years, 25.7% of the 
patients were women, and 40.0% had diabetes 
(Table 1). Most participants had undergone pre-
vious revascularization procedures (66.7% of the 
patients had undergone percutaneous coronary 
intervention, and 14.0% coronary-artery bypass 
grafting). At baseline, antithrombotic agents were 
taken by 95.0% of the patients, lipid-lowering 
agents by 93.4%, anti-ischemia agents by 91.4%, 
and inhibitors of the renin–angiotensin system 
by 79.7%. The median high-sensitivity C-reactive 
protein level at trial entry was 4.20 mg per liter, 
and the median LDL cholesterol level was 82.4 mg 
per deciliter (2.13 mmol per liter).
Effects on Inflammatory Biomarkers  
and Lipid Levels
At 48 months, the median reduction from base-
line in the high-sensitivity C-reactive protein level 
was 26 percentage points greater in the group 
that received the 50-mg dose of canakinumab, 
37 percentage points greater in the 150-mg group, 
and 41 percentage points greater in the 300-mg 
group than in the placebo group (P<0.001 for all 
comparisons of the median percentage change 
in a canakinumab group with the placebo group) 
(Fig. 1, and Fig. S2 and Tables S1 through S5 in 
the Supplementary Appendix). Similar effects 
were observed for the interleukin-6 level (mea-
sured up to 12 months). By contrast, canakinumab 
use resulted in no significant reduction from 
baseline in the LDL cholesterol or HDL choles-
terol level and in a 4 to 5% median increase in 
the triglyceride level.
Follow-up and Effects on Clinical End Points
By the end of follow-up, 18.1% of patients in the 
placebo group had discontinued the trial regi-
men, as compared with 18.7% of patients in the 
combined canakinumab groups (Fig. S1 in the 
Supplementary Appendix). At a median follow-up 
of 3.7 years, the incidence rate for the primary 
end point (nonfatal myocardial infarction, non-
fatal stroke, or cardiovascular death) was 4.50 
events per 100 person-years in the placebo group, 
4.11 events per 100 person-years in the group 
that received the 50-mg dose of canakinumab, 
3.86 events per 100 person-years in the 150-mg 
group, and 3.90 events per 100 person-years in 
the 300-mg group (Table 2). No significant effect, 
as compared with placebo, was observed with 
regard to the primary end point in the 50-mg 
group (hazard ratio, 0.93; P = 0.30) (Fig. 2A). By 
contrast, a significant effect for the primary end 
point was observed in the 150-mg group (hazard 
ratio vs. placebo, 0.85; P = 0.02075, with a thresh-
old P value of 0.02115) (Fig. 2B). In the 300-mg 
group, the hazard ratio was similar to that in the 
Figure 1. Effects of Canakinumab, as Compared with Placebo, on Plasma 
Levels of High-Sensitivity C-Reactive Protein, Low-Density Lipoprotein (LDL) 
Cholesterol, High-Density Lipoprotein (HDL) Cholesterol, and Triglycerides.
Shown are the median percentage changes from baseline (dashed line). 
Specific data points, as well as data regarding interleukin­6 levels at 3 months 
and 12 months, are presented in Tables S1 through S5 in the Supplementary 
Appendix.
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150-mg group, but the P value did not meet the 
prespecified threshold for significance (hazard 
ratio vs. placebo, 0.86; P = 0.0314, with a threshold 
P value of 0.01058) (Fig. 2C). The P value for 
trend across the canakinumab dose groups as 
compared with the placebo group was 0.02, and 
the P value for the comparison of all canakinumab 
doses combined with the placebo group was 0.02 
(both results not adjusted for multiple testing).
For the key secondary cardiovascular end point 
(the components of the primary end point plus 
hospitalization for unstable angina that led to 
urgent revascularization), the incidence rate was 
5.13 events per 100 person-years in the placebo 
group, 4.56 events per 100 person-years in the 
group that received the 50-mg dose of canakinu-
mab, 4.29 events per 100 person-years in the 
150-mg group, and 4.25 events per 100 person-
Figure 2. Cumulative Incidence of the Primary End Point and the Key Secondary Cardiovascular End Point.
Shown is the cumulative incidence of the primary end point of nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death  
in the placebo group versus the various canakinumab dose groups (Panels A through C). The insets show the same data on an enlarged 
y axis. The threshold P value for the primary end point was 0.02115 in the 150­mg group and 0.01058 in the 300­mg group. The group 
receiving the 150­mg dose of canakinumab met the prespecified multiplicity­adjusted threshold for statistical significance for the primary 
cardiovascular end point and for the key secondary cardiovascular end point that additionally included hospitalization for unstable angina 
that led to urgent revascularization (Panel D). The threshold P value for the key secondary cardiovascular end point in the 150­mg group 
was 0.00529.
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years in the 300-mg group (Table 2). In the group 
that received the 150-mg dose of canakinumab 
(for which the P value met the significance 
threshold for the primary end point), the hazard 
ratio versus placebo for the secondary cardiovas-
cular end point was 0.83 (P = 0.00525, with a 
threshold P value of 0.00529) (Fig. 2D). Accord-
ing to the closed testing procedure, formal sig-
nificance testing for the prespecified secondary 
end point was not performed for the 50-mg 
group and the 300-mg group. The hazard ratio 
versus placebo in the 50-mg group was 0.90, and 
the hazard ratio versus placebo in the 300-mg 
group was 0.83 (Figs. S3 and S4 in the Supple-
mentary Appendix). The P value for trend across 
the canakinumab groups as compared with the 
placebo group was 0.003, and the P value for the 
comparison of all canakinumab doses combined 
with the placebo group was 0.001 (both results 
not adjusted for multiple testing).
Analyses of the additional secondary end 
points and of the components of the primary 
and secondary end points were not adjusted for 
multiple testing (Table 2). Nominally significant-
ly lower rates than in the placebo group were 
seen with regard to myocardial infarction in the 
group that received the 150-mg dose of canakinu-
mab; with regard to hospitalization for unstable 
angina that led to urgent revascularization in the 
150-mg group and the 300-mg group; and with 
regard to any coronary revascularization in all 
three dose groups. All-cause mortality was neu-
tral in the comparison of all canakinumab doses 
with placebo (hazard ratio, 0.94; 95% confidence 
interval, 0.83 to 1.06; P = 0.31).
In analyses that focused on patients who ad-
hered to the trial regimen, the observed hazard 
ratios were 1.00 in the placebo group, 0.90 in 
the group that received the 50-mg dose of 
canakinumab, 0.83 in the 150-mg group, and 
0.79 in the 300-mg group (P = 0.003 for trend 
across groups). In similar analyses for the key 
secondary cardiovascular end point, the corre-
sponding hazard ratios were 1.00, 0.88, 0.80, 
and 0.77 (P<0.001 for trend across groups).
Adverse Events and Other Clinical Outcomes
Neutropenia was more common among patients 
who were assigned to receive canakinumab than 
among those in the placebo group, and signifi-
cantly more deaths were attributed to infection 
or sepsis in the pooled canakinumab groups 
than in the placebo group (incidence rate, 0.31 
vs. 0.18 events per 100 person-years; P = 0.02) 
(Table 3). The patients who died from infection 
tended to be older and more likely to have dia-
betes than those who did not die from infection. 
Six confirmed cases of tuberculosis occurred 
during the trial, with similar rates in the pooled 
canakinumab group and the placebo group 
(0.06% in each group); five cases occurred in 
India and one in Taiwan.
Thrombocytopenia was more common among 
patients who were assigned to receive canakinu-
mab than among those in the placebo group, 
but no significant difference in the incidence of 
hemorrhage was observed. The incidence rate of 
injection-site reaction did not differ significantly 
between any canakinumab group and the placebo 
group. In a finding that was consistent with 
known effects of interleukin-1β inhibition, cana-
kinumab resulted in significantly fewer reports 
of arthritis, gout, and osteoarthritis than did pla-
cebo (Table 3). Cancer mortality was significantly 
lower with canakinumab than with placebo.16
Discussion
CANTOS was designed to test directly the inflam-
matory hypothesis of atherothrombosis. In this 
trial, in patients with a history of myocardial 
infarction, the levels of high-sensitivity C-reac-
tive protein and interleukin-6 were significantly 
reduced from baseline by canakinumab, as com-
pared with placebo, with no significant reduc-
tion in lipid levels from baseline. Although the 
50-mg dose of canakinumab did not have a sig-
nificant effect on the primary cardiovascular end 
point as compared with placebo, patients in the 
150-mg group had a risk of the primary end point 
that was 15% lower than the risk in the placebo 
group (3.86 vs. 4.50 events per 100 person-years) 
and a risk of the key secondary cardiovascular 
end point that was 17% lower than that in the 
placebo group (4.29 vs. 5.13 events per 100 person-
years). The P values for both end points met the 
prespecified multiplicity-adjusted thresholds for 
statistical significance. Although the hazard ratios 
for the comparison of canakinumab with placebo 
in the 300-mg group were similar to those in the 
150-mg group, the prespecified thresholds for 
significance were not met in this group. However, 
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both a pooled analysis of all canakinumab doses 
and a trend analysis suggested a beneficial effect 
of canakinumab with regard to cardiovascular 
outcomes.
The specific targeting of interleukin-1β as a 
cytokine-based therapy for the secondary pre-
vention of atherosclerotic events rests on several 
observations. The proinflammatory cytokine 
interleukin-1β plays multiple roles in the devel-
opment of atherothrombotic plaque, including 
the induction of procoagulant activity, the pro-
motion of monocyte and leukocyte adhesion to 
vascular endothelial cells, and the growth of 
vascular smooth-muscle cells.17-19 In mice, inter-
leukin-1β deficiency reduces lesion formation, 
whereas in cholesterol-fed pigs, exposure to ex-
ogenous interleukin-1β increases intimal medial 
thickening.20,21 The NOD-like receptor protein 3 
(NLRP3) inflammasome activates interleukin-
1β, a process promoted by cholesterol crystals, 
neutrophil extracellular traps, tissue hypoxia, 
and arterial f low patterns that are known to 
promote focal development of atherosclerosis 
within arteries.22-25 This activation of interleukin-
1β stimulates the downstream interleukin-6–
receptor signaling pathway, which has been 
implicated by mendelian randomization studies 
as a potential causal pathway for atherothrom-
bosis.26,27 More recently, studies in parabiotic 
mice28 and studies of clonal hematopoiesis29,30 
have implicated interleukin-1β in processes by 
which bone marrow activation accelerates athero-
sclerosis. Furthermore, the expression of specif-
ic inflammasome gene modules affecting inter-
leukin-1β has been associated with death from 
any cause and increased atherosclerosis in elderly 
patients.31
Although the patients in CANTOS had gener-
ally well-controlled levels of LDL cholesterol, rates 
of both the primary end point and the secondary 
cardiovascular end point in the placebo group 
were high, with cumulative incidences of more 
than 20% at 5 years. Our data thus affirm that 
statin-treated patients with residual inflammatory 
risk as assessed by means of a high-sensitivity 
C-reactive protein level of 2 mg or more per liter 
at baseline have future event rates that are at 
least as high as, if not higher than, those among 
statin-treated patients with a residual risk due to 
LDL cholesterol level. These two groups of pa-
tients may differ and may require personalized 
approaches to treatment.32 Despite the fact that 
no significant reduction in cholesterol levels oc-
curred in this trial, the magnitude of effect on 
cardiovascular events with canakinumab (given 
every 3 months) was similar to that associated 
with monoclonal antibodies targeting proprotein 
convertase subtilisin–kexin type 9 (PCSK9; given 
every 2 to 4 weeks).33,34 Yet, inhibition of inter-
leukin-1β is a narrowly focused intervention that 
represents only one of many potential anti-
inflammatory pathways that might serve as tar-
gets for atheroprotection.35-37 Thus, our data sug-
gest that other antiinflammatory interventions, 
such as those that directly inhibit NLRP3 func-
tion or that alter downstream interleukin-6 sig-
naling, may also be beneficial in reducing cardio-
vascular risk.
We found a significantly higher incidence of 
fatal infection and sepsis with canakinumab than 
with placebo, as well as a reduction in platelet 
counts with no increase in bleeding risk. By 
contrast, cancer mortality was significantly low-
er among patients assigned to receive canakinum-
ab than among those in the placebo group, a 
finding that is consistent with experimental data 
relating interleukin-1 to the progression and in-
vasiveness of certain tumors, particularly lung 
cancer.16,38,39 There was no significant difference 
between the canakinumab groups and the pla-
cebo group in all-cause mortality. No statisti-
cally or clinically significant hepatic toxic effect 
was noted. The beneficial effects of canakinu-
mab that were observed with regard to arthritis, 
gout, and osteoarthritis are consistent with well-
described effects of the interleukin-1 and inter-
leukin-6 pathways in these disorders.
In conclusion, in CANTOS, patients with a 
history of myocardial infarction and a high-
sensitivity C-reactive protein level of 2 mg or 
more per liter were randomly assigned to one 
of three doses of canakinumab or to placebo. 
Canakinumab significantly reduced high-sensi-
tivity C-reactive protein levels from baseline, as 
compared with placebo, without reducing the 
LDL cholesterol level, and the 150-mg dose re-
sulted in a significantly lower incidence of recur-
rent cardiovascular events than placebo.
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